Bortezomib-associated rash: a new recognizable and avoidable side-effect

Dermatose neutrophilique aiguë induite par le bortezomib

“…Un syndrome de Sweet n'a été rapporté que chez trois patients porteurs d'un myélome multiple traité par bortezomib : lors de la seconde [17] ou la quatrième injection du deuxième cycle [18], mais aussi dès la première administration chez le troisième patient [18]. Ont également été décrits, sous diverses dénominations, plusieurs cas d'éruptions cutanées se rapprochant cliniquement du syndrome de Sweet, mais d'histologie différente ou ambiguë [19].…”

Bortezomib‐induced cutaneous lupus in a patient with myeloma

“…The types of rashes reported include: drug hypersensitivity, vasculitis, Sweet's syndrome and lupus erythematosus tumidis. 2,3 BAR is usually asymptomatic and not associated with constitutional symptoms. It usually resolves with systemic corticosteroids and the severity generally does not lead to modification of treatment regimen.…”

“…It usually resolves with systemic corticosteroids and the severity generally does not lead to modification of treatment regimen. 3 In animal models with lupus-like disease, bortezomib has been shown to deplete autoreactive plasma cells and serum autoantibody levels 4 and may be a potentially new treatment strategy for systemic lupus erythematosus and other antibodymediated diseases. 4 Although there is a reported association between myeloma and lupus, 5 our patient only presented with a lupus rash after bortezomib was commenced.…”

Persistent supravenous eruption induced by intravenous bortezomib therapy

“…Cutaneous eruption is a relatively common toxicity seen in MM patients treated with bortezomib, and recently it has been well characterized 2,3 . Typically, skin lesions induced by bortezomib are characterized by an asymptomatic maculopapular or nodular rash located on the trunk and face that appears after at least two cycles, and recurs with more severity with subsequent cycles.…”